Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01453946 · ClinicalTrials.gov registry record · Phase 3

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

A Phase 3 study of Crohn's Disease, sponsored by Padagis.

Completed
Registry status
Phase 3
Development phase
55
Enrollment target
19
Study locations

NCT01453946 is a Phase 3 study of Crohn's Disease that has completed, run by Padagis. The registered enrollment target is 55 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (98% lower). The trial reports 19 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01453946, a Phase 3 study of Crohn's Disease, has completed, sponsored by Padagis.

COMPLETED
Registry status
Phase 3
Development phase
55 participants
Enrollment target
19
Study locations

Study Summary

A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

Conditions Studied

Interventions

  • DRUG Entocort

Study Locations (19)

Other

  • Research Site - München
  • Research Site - Nuremberg
  • Research Site - Florence
  • Research Site - Messina
  • Research Site - Roma
  • Research Site - Krakow
  • Research Site - Lodz
  • Research Site - Rzeszów
  • Research Site - Warsaw
  • Research Site - Wroclaw

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Oak Lawn

Massachusetts

  • Research Site - Newton

Minnesota

  • Research Site - Saint Paul

New Jersey

  • Research Site - Mays Landing

New York

  • Research Site - Buffalo

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2011-12
Est. Completion 2014-02
Phase Phase 3

Sponsor

Padagis

17 total trials

What the Registry Record Tells You About NCT01453946

The ClinicalTrials.gov registry entry for NCT01453946 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Entocort is the first listed.

NCT01453946 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Other, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT01453946 about?

NCT01453946 is a clinical study titled "Safety and Maintenance Study of Entocort for Children With Crohn's Disease". A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

What is the current status of trial NCT01453946?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2011-12. Estimated completion is 2014-02.

What conditions does trial NCT01453946 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT01453946?

The interventions under investigation include: Entocort (DRUG).

Who is sponsoring clinical trial NCT01453946?

This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01453946 being conducted?

This trial has 19 study locations across Georgia, Illinois, Massachusetts, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.